Shelly Wong Biography and Net Worth

Chief Accounting Officer of ALX Oncology

Ms. Wong has served as our Senior Vice President Finance and Chief Accounting Officer since August 2023. Prior to 2023, she served as our Vice President Finance and Chief Accounting Officer since May 2021. Before joining ALX Oncology, Ms. Wong was with Tizona Therapeutics, Inc. from July 2016 to April 2021, where she most recently served as Vice President of Finance and Operations. Prior to Tizona, Ms. Wong was the Corporate Controller at InSite Vision Inc. from December 2008 to July 2016, the Assistant Controller at Bare Escentuals, Inc. from May 2007 to November 2008, and Director of Corporate Accounting and Financial Reporting at Dreyer’s Grand Ice Cream Holdings, Inc. from March 2002 to May 2007. Ms. Wong started her career in the audit practice at Deloitte and Touche LLP after graduating with a Bachelor of Science degree in business administration with a major in accounting from Montana State University. She is a Certified Public Accountant.

What is Shelly Wong's net worth?: The estimated net worth of Shelly Wong is at least $176.80 thousand as of July 1st, 2026. Ms. Wong owns 88,401 shares of ALX Oncology stock worth more than $176,802 as of July 15th. This net worth evaluation does not reflect any other investments that Ms. Wong may own. Learn More about Shelly Wong's net worth.
How do I contact Shelly Wong?: The corporate mailing address for Ms. Wong and other ALX Oncology executives is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. ALX Oncology can also be reached via phone at 650-466-7125 and via email at [email protected]. Learn More on Shelly Wong's contact information.
Has Shelly Wong been buying or selling shares of ALX Oncology?: Over the course of the past ninety days, Shelly Wong has sold $2,864.16 in shares of ALX Oncology stock. Most recently, Shelly Wong sold 1,404 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $2.04, for a transaction totalling $2,864.16. Following the completion of the sale, the chief accounting officer now directly owns 88,401 shares of the company's stock, valued at $180,338.04. Learn More on Shelly Wong's trading history.
Who are ALX Oncology's active insiders?: ALX Oncology's insider roster includes Peter Garcia (CFO), Rekha Hemrajani (Director), Jason Lettmann (Director), Jaume Pons (CEO), Sophia Randolph (Insider), and Shelly Wong (Chief Accounting Officer). Learn More on ALX Oncology's active insiders.
Are insiders buying or selling shares of ALX Oncology?: In the last twelve months, ALX Oncology insiders bought shares 3 times. They purchased a total of 3,276,946 shares worth more than $5,099,400.35. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 18,543 shares worth more than $35,895.29. The most recent insider tranaction occured on July, 1st when CAO Shelly Wong sold 1,404 shares worth more than $2,864.16. Insiders at ALX Oncology own 21.0% of the company. Learn More about insider trades at ALX Oncology.
Information on this page was last updated on 7/1/2026.

Shelly Wong Insider Trading History at ALX Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/1/2026	Sell	1,404	$2.04	$2,864.16	88,401

Shelly Wong Buying and Selling Activity at ALX Oncology

ALX Oncology Company Overview

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.94

$1.92

$2.02

50 Day Range

MA: $1.88

$1.38

$2.36

2 Week Range

Now: $1.94

$0.44

$2.66

Volume

74,871 shs

Average Volume

1,048,791 shs

Market Capitalization

$260.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.42